The patent protects InSpan’s unique approach to spinal fixation that allows for less invasive surgery with quicker recovery times and less blood loss in the ASC setting.
In 2021, InSpan became the first interspinous-interlaminar plate fixation device granted the dual FDA approval for spinal fusion and spinal stenosis from T1-S1 in selected patients, according to a March 21 press release.
